Lifespan.io Starting Rapamycin Antiaging Human Trials
Rapamycin is proven to increase the lifespan of yeast, mice and warms. Lifespan.io has started a large-scale clinical trial called Participatory Evaluation of Aging with Rapamycin for Longevity, or PEARL to determine if Rapamycin’s antiaging effects are applicable to humans. This is the first study that will determine if Rapamycin has similar effects in humans to those in mice.
PEARL will test four different Rapamycin dosage regimens over a period of 12 months. The trial will be double-blinded, randomized and placebo-controlled, as well as registered at clinicaltrials.gov. The principal investigator at UCLA is Dr. James P Watson, who also served as a PI in the famous TRIIM study.
Both after six and twelve months, tests and measurements will take place. They will include autonomic tests, blood tests and body composition tests.
Source:
